Lantheus Holdings Inc Revenue Growth Rates (LNTH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lantheus Holdings Inc   (NASDAQ: LNTH)
 

LNTH's Revenue Growth by Quarter and Year

Lantheus Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LNTH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 388.18
1st Quarter March 376.92
FY 765.10

LNTHs Annual Revenue
Lantheus Holdings Inc 's Revenue in the fiscal year 2025 $ 1,540.95 millions
Lantheus Holdings Inc 's Revenue in the fiscal year 2024 $ 1,533.29 millions
Lantheus Holdings Inc 's Revenue in the fiscal year 2023 $ 1,295.54 millions
Lantheus Holdings Inc 's Revenue in the fiscal year 2022 $ 935.06 millions
Lantheus Holdings Inc 's Revenue in the fiscal year 2021 $ 425.21 millions




LNTH Revenue second quarter 2026 Y/Y Growth Comment
Lantheus Holdings Inc reported Revenue growth of 2.69% year on year in the second quarter 2026, to $ 388.18 millions, this is lower than Lantheus Holdings Inc 's recent average Revenue increase of 19.12%.

Looking into second quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Lantheus Holdings Inc ' s Revenue increase of 2.69% ranks overall at the positon no. 2502 in the second quarter 2026.


LNTH Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 3.92 % 10.57 % 34.56 %
3rd Quarter September - 1.39 % 18.55 % 33.29 %
2nd Quarter June 2.69 % -4 % 22.4 % 43.8 %
1st Quarter March 1.13 % 0.77 % 22.96 % 44 %
FY   - 0.5 % 18.35 % -

Financial Statements
Lantheus Holdings Inc 's second quarter 2026 Revenue $ 388.18 millions LNTH's Income Statement
Lantheus Holdings Inc 's second quarter 2025 Revenue $ 378.01 millions Quarterly LNTH's Income Statement


LNTH Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 6.13 % 3.55 % 11.02 %
3rd Quarter September - 1.42 % -3.97 % -0.85 %
2nd Quarter June 2.99 % 1.42 % 6.47 % 6.96 %
1st Quarter March -7.36 % -4.81 % 4.44 % 14.29 %
FY (Year on Year)   - 0.5 % 18.35 % -


Back to LNTH Growth rate Comparisons >> Back to LNTH Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #359
Overall #2502

Revenue Y/Y Growth Statistics
High Average Low
134.43 % 19.12 % -22.98 %
(Dec 31 2022)   (Jun 30 2020)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #359
Overall #2502
Revenue Y/Y Growth Statistics
High Average Low
134.43 % 19.12 % -22.98 %
(Dec 31 2022)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Lantheus Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
61.22 % 4.07 % -27.22 %
(Mar 31 2022)  


LNTH's II. Quarter Q/Q Revenue Comment
Lantheus Holdings Inc achieved in the II. Quarter 2026 below company average Revenue growth of 2.99% quarter on quarter, to $ 388.18 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 1.42% growth in the II. Quarter a year ago

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Lantheus Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1339.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #188
Overall #1339
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #188
Overall #1339
Revenue Q/Q Growth Statistics
High Average Low
61.22 % 4.07 % -27.22 %
(Mar 31 2022)  


LNTH's II. Quarter Q/Q Revenue Comment
Lantheus Holdings Inc achieved in the II. Quarter 2026 below company average Revenue growth of 2.99% quarter on quarter, to $ 388.18 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.42% in the II. Quarter a year ago.

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Lantheus Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1339.


Lantheus Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,555.34 $ 1,545.17 $ 1,540.95 $ 1,525.62 $ 1,520.38
Y / Y Revenue Growth (TTM) 2.3 % 0.59 % 0.5 % 1.99 % 5.83 %
Year on Year Revenue Growth Overall Ranking # 1981 # 1019 # 672 # 515 # 393
Seqeuential Revenue Change (TTM) 0.66 % 0.27 % 1 % 0.34 % -1.03 %
Seq. Revenue Growth (TTM) Overall Ranking # 2728 # 2138 # 1947 # 1774 # 1498


Cumulative Revenue growth Comment
Although Lantheus Holdings Inc 's Annual Revenue growth year on year were below company's average 19.48% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.3% year on year, from 0.59% in Mar 31 2026.

In the Healthcare sector 304 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1019 to 1981.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 305
Overall # 1981

Revenue TTM Y/Y Growth Statistics
High Average Low
119.91 %
 19.48 %
-4.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 388
S&P 500 # 2728
Cumulative Revenue growth Comment
Although Lantheus Holdings Inc 's Annual Revenue growth year on year were below company's average 19.48% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.3% year on year, from 0.59% in Mar 31 2026.

In the Healthcare sector 304 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1019 to 1981.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 305
Overall # 1981

Revenue TTM Y/Y Growth Statistics
High Average Low
119.91 %
19.48 %
-4.48 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 388
S&P 500 # 2728




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LNTH's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Mettler toledo International Inc 4.48%$ 4.485 millions
Phibro Animal Health Corporation4.40%$ 4.405 millions
Align Technology inc 4.35%$ 4.355 millions
Opko Health Inc 4.32%$ 4.319 millions
Dariohealth Corp 4.29%$ 4.291 millions
Orthofix Medical Inc 4.15%$ 4.147 millions
Pediatrix Medical Group Inc 4.04%$ 4.040 millions
Nrc Health3.98%$ 3.978 millions
Bioventus Inc 3.76%$ 3.757 millions
Heron Therapeutics Inc 3.64%$ 3.640 millions
Prime Medicine Inc 3.50%$ 3.498 millions
Inogen Inc 3.04%$ 3.042 millions
Pacific Health Care Organization Inc2.79%$ 2.786 millions
Quidelortho Corp2.77%$ 2.769 millions
C4 Therapeutics Inc 2.75%$ 2.754 millions
Surgery Partners Inc 2.75%$ 2.748 millions
Lantheus Holdings Inc 2.69%$ 2.690 millions
Healthcare Services Group Inc 2.69%$ 2.686 millions
Adma Biologics Inc 2.61%$ 2.613 millions
Pfizer Inc2.60%$ 2.600 millions
Infusystem Holdings Inc2.59%$ 2.586 millions
Outset Medical Inc 2.49%$ 2.488 millions
3m Company2.46%$ 2.459 millions
Strata Critical Medical Inc 2.41%$ 2.408 millions
Nature s Sunshine Products inc 2.35%$ 2.350 millions
Solventum Corporation2.22%$ 2.221 millions
Adc Therapeutics Sa2.17%$ 2.171 millions
Moderna Inc 2.11%$ 2.113 millions
Co diagnostics Inc 1.98%$ 1.977 millions
Rxsight Inc 1.66%$ 1.660 millions


About Lantheus Holdings Inc Revenue Growth Rates (LNTH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lantheus Holdings Inc (CIK 1521036).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-336795
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lantheus Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.